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The presence of infections caused either by hepatitis B or C viruses or both of them 
complicates the evolution of chronic renal failure considerably.The aim of our investigation 
was to determine the presence of hepatotropic viral markers, clinical and laboratory 
characteristics, as well as therapeutic possibilities for examined patients. 
Our investigation included 136 patients who had had regular dialysis tretment. Based 
on the presence of viral markers, all the patients were divided in three groups: (I) HBV 
positive patients; (II) HCV positive patients, (III) HBV and HCV positive  patients. All the 
patients were subdivided in two groups: those with an acute form and those with a chronic 
form based on the clinical course of the disease.The laboratory analysis did not show a 
clear correlation with the course of the disease, especially in those patients with a chronic 
disease. These finding allow us to draw the following conclusions: a significant number of 
patients have been infected with hepatitis B and C viruses; laboratory analysis in patients 
with a chronic course did not always correlate with the evolution of the disease; the clinical 
course is mostly mild. 
Introducing antiviral therapy gives a much better perspective to all categories of 
patients. Acta Medica Medianae 2008;47(3):5-8. 
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Introduction 
 
The liver disese caused by hepatitis B and 
C viruses has become the important cause of 
morbidity and mortality in patients with chronic 
renal insufficiency. 
Infections by hepatitis B  and C viruses had 
a different outcome by the end of the last millenium. 
With the development of diagnostic tests as well 
as carrying out prevention measures, the 
decresing of incidence and prevalence of hepatitis 
B infection has been reached. On the other side, 
liver damage caused by hepatitis C virus has 
different characteristics. The main characterictics 
of hepatitis C are transmission without common 
risk factors, absence of biohemical indicators in 
spite of viremia and false negative serological 
tests (1). Prevalence of anti-HCV positivity in 
patients on hemodyalisis are differentely mani-
fested, from 8.9% to 75% (Moldavia).The main 
characteristic of prevalence is big geografic and 
individual variability among hemodialisis centers 
(2). With the aim of authentic follow-up of patients, 
it is necessary to examine a blood sample to HCV 
RNA before starting the hemodyalisis. 
Acute infection of HCV in hemodialysis 
patients is followed by moderate increasing of 
ALT level and returnig to normal level. The 
beginning of viremic phasis is associated with   
ALT activity (till 74 IU/I), prior to anti-HCV 
seroconversion,  then is followed by persistant 
viremia, normal ALT activity and anti-HCV positivity. 
However, investigations and experiences showed 
that around 25% of patients with HCV infection 
had had normal values of ALT (till 74 IU/I), and 
not only patients on hemodyalisis (1,3,4). Forty 
percents of patients had minimal dissenting from 
normal ALT values (5). 
Relation of ALT level and histological 
finding is not often in correlation, so the decision 
on starting with the treatment is based on 
presence of fibrosis grade after liver  biopsy. 
(6,7). Administration of recombinant alfa-2a 
interferon or pegilated interferon is indicated in 
the treatment of patients in terminal stage of 
renal insufficency(8). New preliminary results 
have shown that interferon application is safe in 
patients coinfected with HBV and HCV infections, 
untill Ribavirin administration is contraindicated 
(8). The aims of the administered therapy for 
hepatitis B viral infection (interferon, lamivudin, 
adefovir) as well as for hepatitis C viral infection 
(pegilated interferon) are stable eradication of 
virus, regression of chronic hepatitis, prevention Chronic renal failure associated with hepatitis B and C...             Velimir Kostic et al. 
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of terminal stage of disease (liver cirrhosis) and 
hepatocellular carcinoma (10). 
 
Material, methods and aim of the study 
 
The investigation involved 136 patients on 
hemodialysis programme, during 2004 and the 
beginning of 2005. All examined patients were 
devided by scrining tests (ELISA test) in three 
groups on the basis of the presence of HBs Ag 
and anti-HCV antibodies. ELISA test was done in 
serological laboratory of the Infectious Diseases 
Clinic. The first group included HBs Ag positive   
patients on hemodialysis programme (29/136). 
The second group were  patients with combinated 
HBV and HCV infection (18/136). The aims of the 
investigation were numerous and included clinical 
and biochemical analyses of patients, determina-
tion of presence of HBV and HCV markers and 
consideration of therapeutic investigations. 
 
Results  
 
During 2004 and the beginning of 2005 there 
were 136 patients tested, with terminal renal inuffi-
cency on the hemodalysis programme by ELISA. 
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Picture 1. Patients distribution by sex 
 
 
The screening tests for diagnosis HBV and 
HCV infections were done. The patients made 
heterologous group (age from 23 to 82). Most of 
the patients (48) belonged to age group from 65 to 
74 years, the smallest number of patients (4) were 
younger than 35 years. Sex distribution showed the 
predominance of male sex.  
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Picture 2. Presence of hepatitis markers 
Regarding the results, all patients were 
divided into three groups. The first group were 
patients anti-HCV positive (89/136)-more numerous 
than other groups. The second group were HBs Ag 
positive (29/136). The third group were patients 
coinfected with HBV and HCV (18/136). The 
duration of hemodalysis programme were various, 
from 1 to 13 years (Picture 2). 
The clinical picture was acute disease (7) 
(Picture 3) with finding HBs Ag, high level of 
bilirubines (≥ Xsr 209 mmol/l), elevated values of 
gama-GT (Xsr=230 UI), aminotransferasis (AST 
Xsr=430 U/l, ALT Xsr=710 U/l) and LDH (Xsr=760 
U/l više). Zika Biochemical aspect of illnes is 
manifested by dyspeptic problems, discoloured 
urine, icterus with severe pruritus, hepatomegaly 
and splenomegaly as main clinical presentation of 
infection. Other patients, with HbsAg, AtHCV or 
conjoined infection were almost asymptomatic 
except some light form of pruritus, hepatomegaly 
or fatigue. The levels of aminotranspherasis,well- 
known as a leading biochemical marker of liver 
malfunction, were differently detectable. The scale 
was expanded from normal or subnormal values to 
lightly alterated. (AST Xsr =52 U/l), (ALT Xsr= 62 
U/l). Sometimes, these analyses could be 
misdiagnosed at first sight. Analysed patients often 
had pathological values o f  g a m a  g l u t a m y l  
transferase up to Xsr=96 U/l. Within these patients, 
there`s a little group of patients who had had the 
liver biopsy performed with the aim of kidney 
transplantation and antiviral treatement (5). 
Pathohistological findings showed active form 
of chronical hepatitis (HAI 5-11) and moderately 
active chronic hepatitis (fibrosis O-2). 
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Picture 3 . Clinical picture of HBV and HCV infections 
 
Discussion 
 
Analysed patients showed very heterogenic 
group. Most of them had monoviral infection 
(118), but 18 had the so-called dual infection. 
Clinical manifestation of acute liver disease in 
hemodialysed patients corresponeded to clinical 
manifestations in the rest of population. 
Chronic forms of hepatitis B and C infections 
have asymptomatic course with light symptoms 
as fatigue, pruritus or hepatomegaly. This asympto-
matic course could be a reason for misdiagnosis 
and delayed treatment. 
The tests that have been done had a big 
epidemiological and therapeutical importance because 
of administration of current antiviral therapy on time. Acta Medica Medianae 2008,Vol.47                                       Chronic renal failure associated with hepatitis B and C... 
  7
The chronic dialysis program patients have 
a similar interferon therapy response as the other 
with chronic hepatitis C form (8). Everyday high-
doses interferon therapy is not recommended in 
practice. Kidney malfunction does not have influence 
on apsorption, distribution and elimination of 
pegilated interferon, so it is a therapy of choice in 
chronic C hepatitis (11,12). Ribavirin is not indicated 
as a drug of choice in HCV infections because of 
possible red cells hemolysis (8,9). Patients with 
transplanted kidneys as well as with HBV 
infections should be treated by lamivudine (10). 
Newly found patients with HBV were in so-
called „negative apparatus“ group, with valid data 
about regular immunisation against HBV infection. 
More detailed epidemiological investigation showed 
that they had been incompletely vacinated agains 
hepatitis B, before hemodialysis was started. 
Analyses of aminotranspherasis activity showed 
that its levels ranged from normal to slightly 
higer, which corresponds to the literature data 
(2,3,4,5,6). 
 
Conclusion 
 
 
Hemodialysis program patients are in high 
percentage infected with hepatitis C virus, hepatitis 
B virus, or both. Clinical presentation is mostly 
mild with very low or normal activity of 
aminotranpherase enzimes. HBV and HCV 
infected patients should be treated adequatly 
before kidney transplantation is planned. 
Antiviral therapy has its own limits, but 
offers brighter perspective for this kind of chronic 
patients. 
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HRONIČNA BUBREŽNA INSUFICIJENCIJA UDRUŽENA SA VIRUSIMA 
HEPATITISA B I C KAO TERAPIJSKI PROBLEM 
 
Velimir Kostić, Marina Đorđević, Lidija Popović, Emina Kostić, Jovana Đorđević i Karolina Paunović 
 
 
Prisustvo infekcije izazvane virusima B i C, pojedinačno ili udruženo, u značajnoj meri 
komplikuje evoluciju hronične bubrežne insuficijencije. Cilj našeg ispitivanja bio je određivanje 
prisustva markera hepatotropnih virusa, kliničkih i laboratorijskih karakteristika hroničnog 
hepatitisa B i C, kao i terapijskih mogućnosti kod ispitivanih bolesnika. 
Ispitivanjem je obuhvaćeno 136 bolesnika sa programa hronične hemodijalize. Na 
osnovu prisustva virusnih markera svi bolesnici su podeljeni u tri grupe: I sa HBV, II sa 
HCV i III grupa sa udruženom infekcijom prethodna dva virusa. Na osnovu kliničkog toka 
ispitanici su podeljeni na bolesnike sa akutnim i hroničnim oblikom bolesti, pri čemu je 
klinički tok hronične bolesti asimptomatski. Laboratorijske analize nisu u jasnoj koleraciji 
sa tokom bolesti, naročito kod hronične bolesti. Ovakav nalaz dozvoljava da zaključimo da 
su bolesnici u značajnom broju inficirani virusima B i C, da laboratorijske analize hroničnih 
bolesnika nisu uvek u korelaciji sa evolucijom bolesti i da je klinički tok bolesti uglavnom 
blag. Uvođenjem antivirusne terapije nudi se jasnija perspektiva ovoj kategoriji bolesnika. 
Acta Medica Medianae 2008;47(3):5-8. 
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